SciELO - Scientific Electronic Library Online

 
vol.45 issue4Homicide victimization according to racial characteristics in BrazilHospitalization for primary care-sensitive conditions in regional health districts in Southern Brazil author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista de Saúde Pública

Print version ISSN 0034-8910

Rev. Saúde Pública vol.45 no.4 São Paulo Aug. 2011 Epub July 01, 2011

http://dx.doi.org/10.1590/S0034-89102011005000043 

ORIGINAL ARTICLES

 

Factors associated to relapse of leprosy in Mato Grosso, Central-Western Brazil

 

Factores asociados a recidiva en hanseníasis en Mato Grosso, Centro-oeste de Brasil

 

 

Silvana Margarida Benevides FerreiraI, II; Eliane IgnottiIII; Mônica Antar GambaIV

IFaculdade de Enfermagem. Universidade de Cuiabá. Cuiabá, MT, Brasil
IISecretaria Municipal de Saúde de Cuiabá. Cuiabá, MT, Brasil
IIIMestrado em Ciências Ambientais. Universidade Estadual de Mato Grosso. Cáceres, MT, Brasil
IVEscola Paulista de Enfermagem. Universidade Federal de São Paulo. São Paulo, SP, Brasil

Correspondence

 

 


ABSTRACT

OBJECTIVE: To analyze factors associated with relapse of leprosy.
METHODS: Retrospective case-control study including 159 patients older than 15 diagnosed with leprosy attending reference centers for leprosy in five municipalities in the state of Mato Grosso, central-western Brazil. Cases (n=53) were patients with relapsed leprosy diagnosed from 2005 to 2007 who were compared with controls (n=106) matching for gender and operational classification who were considered cured after treatment in 2005. Data was obtained from the local Notifiable Diseases Database, medical records and interviews. For the analyses conditional logistic regression and hierarchical approaches were used.
RESULTS: After adjustment, the following factors were associated with relapse of leprosy: living in rental housing (OR = 4.1; 95%CI: 1.43;12.04); living in houses constructed of wood and mud (OR = 3.2; 95%CI: 1.16;8.76); living with dwellings with more than five people (OR = 2.1; 95%CI: 1.03;4.36); alcohol use disorder (OR = 2.8; 95%CI: 1.17;6.79); irregular treatment (OR =3.8; 95%CI: 1.44;10.02); lack of knowledge about the disease/treatment (OR = 2.6; 95%CI: 1.09;6.13); use of public transportation to get to the clinic (OR = 5.5; 95%CI: 2.36;12.63); clinical form of the disease (OR = 7.1; 95%CI: 2.48;20.52), and treatment regimen (OR = 3.7; 95%CI: 1.49;9.11).
CONCLUSIONS: The predictive factors of relapse are associated with housing conditions, living habits, organization of health services, clinical forms of leprosy and treatment regimen. Health services should educate patients on the disease as well as ensure consistent treatment.

Descriptors: Leprosy, prevention & control. Recurrence. Leprostatic Agents, supply & distribution. Socioeconomic Factors. Case-Control Studies.


RESUMEN

OBJETIVO: Analizar factores asociados a la ocurrencia de recidiva en hanseníasis.
MÉTODOS: Estudio retrospectivo caso-control con 159 pacientes mayores de 15 años diagnosticados con hanseníasis en cinco municipios del Estado de Mato Grosso, Centro-oeste de Brasil, cuyas unidades de salud eran consideradas de referencia para el atendimiento. El grupo de casos incluyó 53 individuos con recidiva de 2005 a 2007 y fue comparado con el grupo control (106 con alta por cura en 2005), pareados por sexo y clasificación operacional. Se usaron datos del Sistema de Información de Agravios de Notificación, Prontuarios y entrevistas. Se utilizó regresión logística condicional y abordaje jerárquico.
RESULTADOS: Posterior al análisis ajustado, se mostraron asociados a la ocurrencia de recidiva: individuos residentes en casas alquiladas (OR=4,1; IC95%:1,43;12,04), en domicilio de madera/tapia (OR=3,2; IC 95%:1,16;8,76), que moraban con más de cinco personas (OR=2,1; IC95%:1,03;4,36), con trastorno por uso de alcohol (OR=2,8;IC95%:1,17;6,79), irregularidad del tratamiento (OR= 3,8; IC95%: 1,44;10,02), sin esclarecimiento sobre la enfermedad/tratamiento (OR= 2,6; IC95%:1,09,6,13), que usaban transporte colectivo para el acceso a la unidad de salud (OR=5,5; IC95%: 2,36;12,63), forma clínica de la enfermedad (OR= 7,1;IC95%: 2,48;20,52) y esquema terapéutico (OR= 3,7; IC95%:1,49;9,11).
CONCLUSIONES: Los factores predictivos de recidiva se relacionan con condiciones de vivienda, hábitos de vida, organización de los servicios de salud, formas clínicas y esquemas terapéuticos. Compete a los servicios de salud ofrecer orientaciones adecuadas a los pacientes, así como garantizar la regularidad del tratamiento.

Descriptores: Lepra, prevención & control. Recurrencia. Agentes Leprostáticos, provisión & distribución. Factores Socioeconómicos. Estudios de Casos y Controles.


 

 

INTRODUCTION

The introduction of multidrug therapy (MDT) for leprosy control marked the decline of leprosy cases in Brazil in recent years.ª However, endemic leprosy has remained a major health concern.b The emergence of drug resistance among other factors is associated with relapse of leprosy.15,c

There were reported 16,063 relapsed cases of leprosy worldwide from 2004 to 2009. There were 1,483 relapsed cases in Brazil in 2009, corresponding to 3.9% of new cases diagnosed during 2009. Relapsed cases of leprosy are not included in the indicator of incidence, i.e., new case detection rate but they affect the prevalence of the disease.b

According to World Health Organization (WHO),22 the estimated risk of relapse after the implementation of MDT is 1.1% for paucibacillary (PB) cases and 0.8% for multibacillary (MB) cases in nine years following treatment. Relapse rates are between 3% and 17% with 2 to 15 years for relapse.4,8,9,21

There are major differences in the relapse rates among Brazilian regions such as the Brazilian legal Amazon border.d The state of Mato Grosso, central-western Brazil, accounted for 6% to 20% of relapsed cases between 2004 and 2006.6

Studies on factors associated with relapsed leprosy are relatively scant in Brazil and most have focused on clinical/laboratory and treatment factors overlooking socioeconomic aspects and those related to health services. They have pointed out the following determinant factors: household contacts,10,24 persistence of bacillus (bacterial index [BI] >2+),4,9,10,24 interval between initial treatment and relapse, clinical form of leprosy, duration/type of MDT and drug reaction events.4,8,10,21,24

The present study aimed to describe factors associated with relapse of leprosy.

 

METHODS

This is a retrospective case-control study including 159 patients older than 15 diagnosed with leprosy attending reference centers for leprosy in five municipalities (Cáceres, Cuiabá, Diamantino, Rondonópolis e Várzea Grande) in the state of Mato Grosso, central-western Brazil.

Cases (n = 53) were patients with relapsed leprosy diagnosed from 2005 to 2007 who were compared with controls (n=106) who were considered cured after treatment in 2005. The controls were matched by gender and operational classification to minimize or eliminate the confounding effect due to the predominance of relapse among MB and male cases.6 The criteria for the diagnosis of relapses in leprosy were based on the Brazilian Ministry of Health protocolse and included new lesions and/or exacerbations of previous lesions, new neurological lesions with inadequate response after treatment with corticosteroids and/or thalidomide and bacteriological and/or histopathological test results consistent with active forms in patients who were considered cured following treatment.

Data from the local Notifiable Diseases Database (SINAN/MT) were used to identify subjects in medical records of health facilities and contact them for an interview. These data included: reporting municipality and facility; date of reporting; date of diagnosis; patient's municipality of residence; patient name; gender; age; entry type; clinical form, operational and therapeutic regimen; degree of disability assessed at diagnosis; date of treatment start and end; and type of cure.

Information on demographic characteristics (age and education), clinical/laboratory features and treatment (clinical form, treatment regimen, frequency of treatment, number, type and site of lesions, nerve thickening, reactive state, side effects, physical disability, BI, skin biopsy and logarithmic index of biopsies) was obtained from medical records, disability assessment forms and reporting forms.

Interviews were carried out to collect information on socioeconomic and epidemiological factors (individual and family monthly income in minimum wages, occupation status, housing status, types of home construction materials, sewage system, garbage collection, number of people living in the dwelling, type of household contact, comorbidities/concurrent conditions and hospitalization); habits (smoking and alcohol use), organization of health services (home visits, guidance, drug availability at the facility, type of transportation to get to the health facility) and variables related to skin color/ethnicity.

BI and skin biopsies were performed at reference laboratories in the state of Mato Grosso and at the Instituto Lauro de Souza Lima, in Bauru, Southeastern Brazil, which is a national reference center. Housing conditions and ethnicity were defined based on the Instituto Brasileiro de Geografia e Estatística (IBGE -Brazilian Institute of Geography and Statistics criteria.f Skin color/ethnicity (white, black, Asian, mixed and native) was self-reported and categorized into mixed (mulatto, mestizo and mixed) and non-mixed (white, black, Asian and native).13 The CAGE questionnaire14 (C: cut-down; A: annoyed; G: guilty; E eye--opener) was used to evaluate alcohol use. The cutoff for the test was two or more positive answers. Patient guidance was defined as two or more information provided on pathogenicity, mode of transmission, treatment and warning signs of disease severity. Regular or irregular treatment was assessed through information on medical records on the duration of supervised monthly doses following the WHO/MDT regimen (PB cases: six doses within nine months; and MB: 12 †doses within 18 months and 24 doses within 36 months). Clinical and treatment criteria were defined according to leprosy control activities.e

Eligibility criteria included: (i) cases: individuals older than 15 diagnosed with relapsed leprosy living in the study municipalities and recorded in the SINAN/MT database between 2005 and 2007 (n = 82). Of them, 17 were excluded due to transfer, diagnostic error, treatment dropout and/or death. Of 65 (79.3%) records, 12 were not located for interview, totaling 53 cases included in the study; (ii) control group: individuals older than 15 living in the municipalities where the cases originated and considered cured in 2005 and who did not relapse until December 31, 2008, completing a three-year interval following treatment. A total of 983 individuals who were considered cured and were recorded as "new case" in the SINAN/MT in 2005 were included. Of these, those who were transferred (n = 251) and double entered (n = 6) were excluded, resulting in 106 controls (2:1).

A hierarchical approach and conditional logistic regression with regression coefficients in terms of logarithmic odds ratio were used.23 Three hierarchical levels including distal, intermediate and proximal level factors were analyzed (Figure). The distal level included socioeconomic variables; the intermediate level was divided into I (demographic and lifestyle factors) and II (factors related to health service organization). This approach allowed measuring the contribution of each hierarchical level and minimizing underestimation of risk effects. The first (distal) level was overdeterminant. The set of variables in this level was analyzed independently from those of other levels and included the adjustments of variables at other subsequent levels when they were statistically significant (p<0.05), in the same order used for other levels. Variables remained in the final model when adjustments were appropriate (Figure). The modeling process included the variables selected in the crude analysis at a 5% significance level. The logistic regression analysis was conducted following the proposed plan for hierarchical approach.

Data were double entered using EpiInfo version 3.2.1 and all statistical analyses were conducted using SPSS 15.0.

The study followed ethical principles and was approved by Research Ethics Committee at Hospital Universitário Júlio Muller (protocol no. 321, April 2007).

 

RESULTS

Of 159 cases and controls, 33.3% were cases and 66.7% controls. The following variables were significantly associated with relapse of leprosy in the univariate analysis: living in rental housing; living in houses constructed of wood and mud; living with more than five people (distal level determinants) (Table 1); mixed skin color, alcohol use disorder, irregular MDT, no guidance on the disease/treatment, and use of buses for transportation to get to the health facility (intermediate levels I and II) (Table 2); clinical form and treatment regimen (proximal level) (Table 3).

The following variables were not associated with relapse: individual and family monthly income, occupation status and sewage system (distal level); age, education, marital status, smoking and number of cigarettes smoked (intermediate level I); home visits (intermediate level II); number, type and site of leprosy lesions, nerve thickening; reactive state, side effects, degree of disability at diagnosis, bacterial index, logarithmic index of biopsies, skin biopsy, type and household contacts of leprosy cases, comorbidities/concurrent conditions, types of comorbidities, and hospitalization (proximal level).

The final model including factors associated with leprosy relapse is shown in Table 4. Those living in rental housing were 4.1 times more likely to relapse than those living in their own home/borrowed homes (95%CI 1.43;12.04). Those living in homes constructed of wood and mud were 3.2 times more likely to relapse than those living homes constructed of masonry (95%CI 1.16;8.76); and relapse was 2.1 times more likely among those living with five or more people (95%CI 1.03;4.36). Individuals of mixed skin color were 60% less likely to relapse compared with those of non-mixed skin color [adjOR = 0.4 (95%CI 0.19;0.84)]. Even after adjustment alcohol use disorder was a major predictor of relapse. Those who had a positive CAGE test were 2.8 times more likely to relapse than those who tested negative (95%CI 1.17;6.79). Relapse was 3.8 times more likely among those who had irregular than those who had regular treatment (95%CI 1.44;10.2). No guidance on disease and treatment increased by 2.6 times the odds of relapse (95%CI 1.09;6.13). Using bus transportation to get to the health facility was strongly associated with the outcome even after adjustment [adjOR = 5.5 (95%CI 2.36;12.63)]. As for clinical form, those classified as other (indeterminate / tuberculoid / lepromatous leprosy) were 7.1 times more likely to relapse compared to borderline forms (95%CI 2.48;20.52). Regarding treatment regimen, relapse in those categorized as other (MDT, 6 and 24 doses) was 3.7 times higher than in those receiving a treatment regimen of 12 doses (95%CI 1.49;9.11).

 

DISCUSSION

Living in rental housing, in houses constructed of wood and mud and with more than five people and use of public transportation to get to the health facility were factors associated with relapse in leprosy. Relapse was more likely in individuals with alcohol use disorder, treatment noncompliance, and who did not receive any guidance on the disease and treatment. The clinical form of leprosy (indeterminate / tuberculoid / lepromatous) and treatment regimen (MDT / 6 and 24 doses) were also associated with relapse.

Mixed skin color was a protective factor for relapse even after adjustment. The majority of the population of Mato Grosso (54.6%) is of mixed skin color,g and it is estimated that 80%-95% of the individuals exposed to the bacillus have natural resistance to leprosy. This finding supports the hypothesis of genetic influence on leprosy.16 This protective association could be explained by cellular immune response to the bacilli and its genetic influence. The potential association between skin color/ethnicity and socioeconomic factors was assessed. However, the variable ethnicity remained associated with relapse after adjusting for covariates at the same level and variables at the distal level.

Alcohol abuse that was identified as a predictive factor for relapse may be explained by the effect of alcohol on the metabolism of certain drugs, mainly antibiotics, affecting their absorption; tissue- and organ-specific effects of alcohol; increased susceptibility to infections; and treatment noncompliance.3,11

Individuals living in rental housing constructed of wood/mud were more likely to relapse. The relationship between unfavorable socioeconomic conditions and higher risk of leprosy has been investigated in other studies.1,2 Unfavorable socioeconomic conditions, poor living conditions and immune response to Mycobacterium leprae are all factors that could favor relapse of leprosy.

Large number of people living in the household was associated with relapse even after adjustment. Overcrowding is a determining factor for disease development.2 But different health conditions may be associated with the spatial and social organization that determines the risk of disease in certain population groups.1 Potential exogenous reinfection could be one explanation. Household contacts of leprosy cases were investigated in this study and a similar distribution of cases and controls was found. Yet, the possibility of exogenous reinfection cannot be ruled out given the high rate of leprosy in the area studied.7

The higher risk of relapse found for MDT regimens of 6 doses compared with 12 doses suggests potential errors in the operational classification of disease in the initial treatment. The choice of treatment regimen should be based on careful evaluation of leprosy cases which can ensure more accurate treatment and higher cure rates; however, a definite diagnosis without laboratory confirmation and/or negative results, especially in bacilliferous cases, can lead to misdiagnosis and subsequent disease reactivation.6 Short-term treatment with insufficient number of drugs to treat patients with low immune response can favor relapse.17 Alternatively serological tests can be used for the classification of PB and MB leprosy in the initial treatment and to confirm suspected relapse.12 Greater risk of relapse was found among those individuals treated with MDT with a 24-dose regimen. This can be explained by disease severity possibly associated with bacterial persistence and specific immune response.4,8,9,16 MB cases treated with 24 doses have higher risk of relapse and are associated with borderline-lepromatous and lepromatous leprosy and high BI (>2+) in initial treatment.4,8 The use of alternative drugs to replace the standard regimen for leprosy treatment should be considered.4,8,18 Antimicrobial combinations seem to be effective but minocycline plus rifampicin only have proven to eliminate all M. leprae; antimicrobial combinations that include rifampin and either ofloxacin, clarithromycin or minocycline can improve treatment effectiveness.4,8,18 However, these more severe cases should receive treatment in specialized centers.e

The organization of health services is apparently the most important factor associated with relapse as it can be changed within the health system. The risk of relapse in individuals who had irregular treatment was almost four times as high as compared to those with regular treatment. Irregular treatment, which is seen as a form of noncompliance, may be related to the patient himself (not complying with prescribed treatment course, incorrect drug use and/or missing medical appointments) or to the organization of services (failure to schedule returns, lack of drugs at the facility, lack of direct supervision of drug treatment, and inadequate relationship between patients and providers).11,19 The risk of relapse for the group of individuals who did not receive any guidance on the disease and treatment was nearly three times higher than that in those who reported receiving guidance. Sociocultural aspects such as knowledge, attitudes and practices about leprosy and access to information may affect treatment compliance.5,11,19 Ongoing patient education and community involvement including strategies to facilitate successful treatment can help the implementation of disease control actions. Successful relapse prevention requires taking responsibility, from political decision-making to health care quality.e

The use of public transportation to get to the health facility proved an important predictor of relapse. In municipalities with specialized care centers, diagnosis and treatment of leprosy are still partially centralized, which may contribute to difficult access to treatment. Patients living close to health facilities have more access to services and thus show greater treatment compliance. This is corroborated by the fact that 48.1% of controls reported not requiring public transportation to get to the health facility, i.e., they lived within the catchment area. Home visits as a protective factor could explain this finding but they were evenly distributed between cases and controls. Decentralization and regionalization have been discussed as a strategy for hierarchization of health services and greater equity, suggesting that there is a need to implement regulatory mechanisms of health care.h

A limitation of the present study is that controls could not be investigated prior to 2005. These individuals could not be interviewed for data collection due to intense population migration within the state of Mato Grosso, especially in the areas studied. Some of the controls included in the study could relapse in the future. However, the methodological approach of matching cases and controls minimized this effect.20

In conclusion, the predictive factors for relapse in leprosy are associated with living conditions, living habits, organization of health services, clinical forms of disease and treatment regimens. To prevent relapse, health services should provide appropriate guidance to patients and ensure regular treatment.

 

REFERENCES

1. Andrade VLG, Sabroza PC, Araújo AJG. Fatores associados ao domicílio e à família na determinação da hanseníase, Rio de Janeiro, Brasil. Cad Saude Publica. 1994;10 Supl 2:S281-S292. DOI:10.1590/S0102-311X1994000800006        [ Links ]

2. Bakker MI, Hatta M, Kwenang A, Van Mosseveld P, Faber WR, Klatser PR, et al. Risk factors for developing leprosy: a population-based cohort study in Indonesia. Lepr Rev. 2006;77(1):48-61.         [ Links ]

3. Brown RL, Dimond AR, Hulisz D, Saunders LA, Bobula JA. Pharmaco-epidemiology of potential alcohol-prescription drug interactions among primary care patients with alcohol-use disorders. J Am Pharm Assoc. 2007;47(2):135-9. DOI:10.1331/XWH7-R0X8-1817-8N2L        [ Links ]

4. Cellona RV, Balagon MVF, de la Cruz EC, Burgos JA, Abalos RM, Walsh GP, et al. Long-term efficacy of 2-year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Leprosy. 2003;71(4):308-19. DOI: 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2        [ Links ]

5. El Hassan LA, Khalil EAG, el-Hassan AM. Socio-cultural aspects of leprosy among the Masalit and Hawsa tribes in the Sudan. Lepr Rev. 2002;73(1):20-8.         [ Links ]

6. Ferreira SMB, Ignotti E, Senigalia LM, Silva DRX, Gamba MA. Recidivas de casos de hanseníase no estado de Mato Grosso. Rev Saude Publica. 2010;44 (4):650-7. DOI:10.1590/S0034-89102010000400008        [ Links ]

7. Gallo MEN, Oliveira MLW. Recidivas e reinfecção em hanseníase. Medicina (Ribeirão Preto). 1997;30(3):351-7.         [ Links ]

8. Gelber RH, Balagon MVF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Leprosy Other Mycobact Dis. 2004;72(4):493-500. DOI:10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2        [ Links ]

9. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev. 2000;71(2):144-53.         [ Links ]

10. Haldar A, Mahapatra BS, Mundle M, Haldar S, Saha AK. A study of relapse after MDT in a district in West Bengal, India. Indian J Lepr. 2003;75(1):1-8.         [ Links ]

11. Ignotti E, Andrade VLG, Sabroza PC, Araújo AJG. Estudo da adesão ao tratamento da hanseníase no município de Duque de Caxias - Rio de Janeiro: "abandonos ou abandonados". Hansen Int. 2001;26 (1):23-30.         [ Links ]

12. Katochi VM, Lavania M, Chauhan DS, Sharma R, Hirawati, Katochi K. Recent advances in molecular biology of leprosy. Indian J Lepr. 2007;79(2-3):151-66.         [ Links ]

13. Maio MC, Monteiro S, Chor D, Faerstein E, Lopes C. Cor/raça no Estudo Pró-Saúde: resultados comparativos de dois métodos de autoclassificação no Rio de Janeiro, Brasil. Cad Saude Publica. 2005;21(1):171-80. DOI: 10.1590/S0102-311X2005000100019        [ Links ]

14. Masur J, Monteiro MG. Validation of the "CAGE" alcoholism screening test in a Brazilian psychiatric inpatient hospital setting. Braz J Med Biol Res. 1983;16(3):215-8.         [ Links ]

15. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev. 2007;78(4):343-52.         [ Links ]

16. Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG. Genetics of host response in leprosy. Lepr Rev. 2006;77:189-202.         [ Links ]

17. Opromola DVA. Ação terapêutica das drogas anti-hansênicas e evidências de persistência microbiana nos casos paucibacilares [editorial]. Hansen Int. 2004;29(1):1-3.         [ Links ]

18. Opromolla DVA. Noções de Hansenologia. Bauru: Centro de Estudos "Dr. Reynaldo Quagliato"; 2000. Terapêutica; p.95-100.         [ Links ]

19. Rodriguez G, Pinto R, Laverde C, Sarmiento M, Riveros A, Valderrama J, et al. Recidivas postratamiento de la lepra multibacilar. Biomédica. 2004;24(2):133-9.         [ Links ]

20. Schlesselman JJ. Case-control studies: design, conduct and analysis. Oxford: Oxford University Press; 1982. (Monograph in Epidemiology and Biostatistics).         [ Links ]

21. Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev. 2005;76(3):241-52.         [ Links ]

22. The Leprosy Unit, WHO. Risk of relapse in leprosy. Indian J Lepr. 1995;67(1):13-26.         [ Links ]

23. Victora CG, Huttly SR, Fuchs SC, Olinto MTA. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997;26(1):224-7. DOI:10.1093/ije/26.1.224        [ Links ]

24. Ximenes RAA, Gallo MEN, Brito MFM. Retreatment in leprosy: a case-control study. Rev Saude Publica. 2007;41(4):632-7. DOI:10.1590/S0034-89102006005000037        [ Links ]

 

 

Correspondence:
Silvana Margarida Benevides Ferreira
Av. Beira Rio, nº 3.100
Jardim Europa 78065-900
Cuiabá, MT, Brasil
E-mail: jffbenev@terra.com.br

Received: 8/27/2010
Approved: 3/9/2011

 

 

Research funded by Fundação de Amparo à Pesquisa do Estado de Mato Grosso (protocol no: PPSUS/275-10036).
Article based on the doctoral thesis of Ferreira SMB submitted to the Paulista School of Nursing, Universidade Federal de São Paulo, in 2009.
The authors declare no conflicts of interest.
a World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities (Plan period: 2006-2010). Geneva; 2005.
b World Health Organization. Global leprosy situation. Wkly Epidemiol Rec. 2010;85(35):337-48.
c World Health Organization. Guidelines for global surveillance of drug resistance in leprosy 2009. http://www.searo.who.int/LinkFiles/Situation_1-Guidelines_GSDRL_GLP-09.pdf
d Ministério da Saúde. Casos confirmados notificados no Sistema de Informação de Agravos de Notificação - Sinan Net/hanseníase 2008.[citado 2008 jun]. Disponível em: http://dtr2004.saude.gov.br/sinanweb/
e Ministério da Saúde. Secretaria de Vigilância em Saúde. Portaria Conjuna Nº 125, de 26 de março de 2009. Define ações de controle da hanseníase. Diário Oficial da União. 27 mar 2009; Seção 1:73.
f Instituto Brasileiro de Geografia e Estatística.. Pesquisa Nacional de Amostra por Domicílios - PNAD 2008. Questionário de pesquisa [citado 2008 abril]. Disponível em:http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad
2008/questpnad2008.pdf

g Instituto Brasileiro de Geografia e Estatística. Contagem da população 2007: população recenseada e estimada, segundo os municípios de Mato Grosso. Rio de Janeiro; 2007.
h Ministério da Saúde. Portaria nº 95, de 26 de janeiro de 2001. Norma operacional da assistência à saúde - NOAS-SUS 01/2001. Diario Oficial Uniao. 29 jan 2006; Seção 1:48.